The therapeutic options for advanced or metastatic renal cell carcinoma (mRCC) have
drastically evolved over the past 20 years. High-dose interleukin-2 (HD IL-2), which led to …

Background Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with
new combination therapies demonstrating improved response rates and survival. There are …

Background Immune checkpoint inhibitors (ICI) have demonstrated impressive activity in
metastatic clear-cell renal cell carcinoma (ccRCC) and have become standard treatment …

Abstract Background Immune checkpoint inhibitors (ICIs) are being increasingly utilised in
the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC). Limited …

Until recently, a dichotomy existed in the front-line approach of metastatic clear-cell renal
cell carcinoma (mRCC). Specifically, patients received either targeted therapy or …

First-line treatment for metastatic clear-cell renal cell carcinoma patients with intermediate
and poor-risk features consists of a combination of immune checkpoint inhibitors (eg …

Background Second-line systemic treatment options for metastatic clear cell renal cell
cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim …

Simple Summary To summarize the main discoveries made over the past few years to treat
metastatic clear cell renal cell carcinoma, including different generations of anti-VEGF TKIs …

Significant strides have been made in the frontline treatment of patients with advanced clear
cell renal cell carcinoma (ccRCC). There are multiple standard-of-care doublet regimens …

Objective To explore the efficacy and safety of pazopanib in a 'real‐world'setting in
unselected patients, as data regarding unselected patients with metastatic clear‐cell renal …